Eupraxia Pharmaceuticals Inc.
EPRX
$5.28
$0.234.55%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 3.07M | 3.27M | 3.60M | 2.22M | 2.58M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 8.26M | 7.12M | 7.48M | 6.27M | 6.56M |
Operating Income | -8.26M | -7.12M | -7.48M | -6.27M | -6.56M |
Income Before Tax | -8.74M | -6.76M | -7.53M | -5.99M | -6.07M |
Income Tax Expenses | 5.60K | 2.80K | 1.80K | -- | -5.00K |
Earnings from Continuing Operations | -8.75M | -6.77M | -7.53M | -5.99M | -6.06M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | 6.80K | 4.70K | 23.40K | 48.00K | 56.70K |
Net Income | -8.74M | -6.76M | -7.51M | -5.94M | -6.01M |
EBIT | -8.26M | -7.12M | -7.48M | -6.27M | -6.56M |
EBITDA | -8.23M | -7.10M | -14.83M | -6.25M | -6.53M |
EPS Basic | -0.24 | -0.21 | -0.43 | -0.17 | -0.17 |
Normalized Basic EPS | -0.15 | -0.12 | -0.13 | -0.10 | -0.11 |
EPS Diluted | -0.24 | -0.21 | -0.44 | -0.17 | -0.17 |
Normalized Diluted EPS | -0.15 | -0.12 | -0.13 | -0.10 | -0.11 |
Average Basic Shares Outstanding | 35.91M | 35.69M | 35.64M | 35.62M | 35.62M |
Average Diluted Shares Outstanding | 35.91M | 35.69M | 35.64M | 35.62M | 35.62M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |